Oncology

Durvalumab, Tremelimumab Granted Orphan Drug Status for Liver Cancer

The US Food and Drug Administration granted Orphan Drug Designation to durvalumab (Imfinzi) and tremelimumab for the treatment of hepatocellular carcinoma (HCC), AstraZeneca said in a press release. Hepatocellular carcinoma is the most common type of liver cancer. According to the American Cancer Society, approximately 42,810 new cases of liver...